Patents by Inventor Amy N. Courtney

Amy N. Courtney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME
    Publication number: 20240325450
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: June 12, 2024
    Publication date: October 3, 2024
    Applicant: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
    Patent number: 12048716
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: July 30, 2024
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
    Patent number: 11458168
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 4, 2022
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • NKT-cell subset for in vivo persistence and therapeutic activity and propagation of same
    Patent number: 11266689
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: March 8, 2022
    Assignee: Baylor College of Medicine
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME
    Publication number: 20200163992
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: June 3, 2019
    Publication date: May 28, 2020
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME
    Publication number: 20180264040
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian
  • NKT-CELL SUBSET FOR IN VIVO PERSISTENCE AND THERAPEUTIC ACTIVITY AND PROPAGATION OF SAME
    Publication number: 20160310532
    Abstract: Embodiments of the disclosure include methods and compositions for producing NKT cells effective for immunotherapy and also methods and compositions for providing an effective amount of NKT cells to an individual in need of immunotherapy. In specific embodiments, the NKT cells are CD62L+ and have been exposed to one or more costimulatory agents to maintain CD62L expression. The NKT cells may be modified to incorporate a chimeric antigen receptor, in some cases.
    Type: Application
    Filed: April 21, 2016
    Publication date: October 27, 2016
    Inventors: Leonid S. Metelitsa, Amy N. Courtney, Gengwen Tian